In a groundbreaking move, Boehringer Ingelheim has sealed the deal to acquire T3 Pharmaceuticals, a dynamic Swiss biotech company, for a staggering amount of up to 450 million CHF. This strategic move signals a major leap
Memo Therapeutics, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF 25 million series C financing round led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group,
Memo Therapeutics, a late-stage biotech firm specializing in top-tier therapeutic antibodies, disclosed the successful conclusion of its CHF 25 million Series C funding round. This milestone was spearheaded by Pureos Bioventures, with strong participation from Memo
Walder Wyss has acted as legal counsel to SkyCell on the completion of a USD 57 million equity financing round at a USD 600 million valuation with M&G Investments, a global investment firm that invests
In a strategic move to enhance its presence in the healthcare sector, Swiss Post, under the legal guidance of Vischer, has acquired a stake in Steriparc, a promising joint venture specializing in the externalized handling
Vischer acted as legal advisor to LimmaTech Biologics as it successfully concluded a USD 37 million (CHF 33 million) Series A financing round, co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund.
On October 4, 2023, Novartis successfully executed the spin-off of Sandoz by distributing Sandoz shares as a dividend-in-kind to Novartis shareholders and American Depositary Receipts (ADRs) holders. Sandoz shares are now listed on the SIX Swiss Exchange.
Homburger advised Tolremo therapeutics on the extension of its Series A financing round, bringing the total amount raised to USD 39 million (CHF 34.1 million). BioMedPartners led the round with participation from a new investor, Pierre Fabre
Novartis has completed the spin-off of Sandoz‘s generics and biosimilars business, with the result that Sandoz Group debuted as an independent, publicly traded company. Sandoz shares were successfully listed on the Swiss stock exchange,
Vischer acted as legal counsel to Afinum in its investment in Hofstetter PCB, the European provider of printed circuit boards plating and special final finishing services. Together with its prior investment in GS Swiss, Afinum
